Performance, transparency, trust

We’re proud of the value we create for all our stakeholders, and strive to communicate our performance in a clear and timely manner. Download the latest reports, or stay up to date on various metrics of our market performance here. If you have any queries not addressed here, please feel free to get in touch with Investor Relations on our Contact page. 


Observe Medical ASA was listed on Oslo Børs 4 November 2019. Our ambition is to provide shareholders, analysts and investors simultaneous access to accurate, clear and relevant information. We aim to make all our communication to the financial market available on this web site. 

Read our latest regulatory news

Observe Medical ASA: Interim report fourth quarter 2020

Oslo, February 23[rd], 2020 – Observe Medical ASA (OSE: OBSRV) today released its presentation of the fourth quarter 2020, reporting continued progress in terms of the commercialization and go-to-market strategy for its first product Sippi®. Sippi® is a unique and proprietary solution for digital automated urine monitoring in hospitals. “Sippi® contributes to improved clinical outcome…

Read more

Observe Medical ASA : Invitation to fourth quarter 2020 presentation

Observe Medical ASA invites you to a presentation of the fourth quarter 2020 on Tuesday February 23 at 8.30 CET. Due to the covid-19 situation the presentation will only be held as a webcast. The event will start at 08.30 CET and will be webcasted on – Investor relations and on the following link:…

Read more

Observe Medical receives significant order for medical consumables from a hospital region in the Nordic market

Oslo 29 January 2021 – Observe Medical ASA (OSE: OBSERV), today announces that Observe Medical Group has received a significant order for medical consumables from a hospital region in the Nordic market. Following the recent acquisition and integration of Sylak AB, Observe Medical has delivered strong sales performance and today announces a significant order for…

Read more

Financial calendar

  • 23.02.21

    Quarterly Presentation – Q4

  • 30.04.21

    Annual Report

  • 12.05.21

    Quarterly Presentation - Q1

  • 21.05.21

    Annual General Meeting

  • 20.08.21

    Half-yearly Report

  • 03.11.21

    Quarterly Presentation - Q3

The Share

Share performance


Last updated 16 February 2021

NameNumber of shares% of top 20% of totalCountry
1NAVAMEDIC ASA 4,222,727  25.43%21.54%Norway
2INGERØ REITEN INV. COMPANY AS 3,939,394  23.73%20.09%Norway
3RO, LARS 1,500,000  9.03% 7.65%NORWAY
5ARTAL AS 990,407 5.97% 5.05%Norway
6ALPINE CAPITAL AS 650,000 3.92% 3.32%Norway
7Soleglad Invest AS 586,668 3.53% 2.99%NORWAY
8NORDA ASA 516,570  3.11% 2.63%Norway
9TRANBERGKOLLEN INVEST AS 500,000  3.01% 2.55%Norway
10LEIKERANE AS 425,666  2.56% 2.17%Norway
11LAPAS AS 348,326 2.10% 1.78%Norway
12MP PENSJON PK 262,025  1.58% 1.34%NORWAY
14GINNY INVEST AS 206,230 1.24% 1.05%NORWAY
15PHILIP HOLDING AS 200,000 1.20% 1.02%norway
16NORDNET BANK AB 137,693 0.83% 0.70%SWEDEN
17Bjørntvedt, EIVIND 130,000 0.78% 0.66%Norway
18cam as 124,303 0.75% 0.63%NORWAY
19ABC INVEST AS 120,000 0.72% 0.61%NORWAY
20BUKKEVIK INVESTERING AS 110,160 0.66% 0.56%Norway
Total numBer owned by top 2016,602,541100.00%84.68%
Total number of shares19,605,457

Basic share data

Stock Exchange:


First day of listing:


Trading Currency:


Number of shares issued:

Nominal value:

Euronext Expand Oslo


4 November 2019




19 605 457

NOK 0.26


Nomination committee

The Articles of Association provide for a nomination committee composed of two or three members. The current members of the nomination committee are Bård Brath Ingerø (chair) and Grete Hogstad.

The nomination committee is responsible for nominating candidates for the election of shareholder-elected members and chairperson to the Board of Directors and for nominating members to the nomination committee, as well as making recommendations for remuneration of these. 

For nomination committee please contact: 

Björn Larsson, Chief Executive Officer
+46 766 201 725 /

IR contact

Björn Larsson, Chief Executive Officer
+46 766 201 725 /

Per Arne Nygård, Chief Financial Officer
+47 41 10 43 45 /

Sign up for the mailing list